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Summary
Low-grade serous ovarian cancer (LGSOC) has less aggressive behavior and a better clinical outcome than high-grade 
serous ovarian cancer (HGSOC). Considering that this malignancy is relatively chemoresistant, surgery is the keystone of 
treatment, with a strong recommendation for maximal cytoreduction. Women with stage IA-IB disease should undergo 
observation alone after primary cytoreductive surgery. In contrast, observation, chemotherapy, or endocrine therapy are 
possible options for those with stage IC-IIA disease. Patients with stage IIB-IV disease receive either chemotherapy with 
carboplatin and paclitaxel for six cycles followed by endocrine therapy, most commonly with aromatase inhibitors, or endo-
crine therapy alone until disease progression or unacceptable toxicity. Surgery, chemotherapy, and endocrine therapy are 
also used in patients with recurrent disease. Targeted agents, especially mitogen-activated protein kinase (MEK) inhibitors 
and cyclin-dependent kinase (CDK) inhibitors, are currently under evaluation in this clinical setting. Additional research on 
the genomics of LGSOC to better define the activating gene mutations involved in the carcinogenesis is strongly warranted 
to improve the prognosis with this malignancy.
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Low-grade serous ovarian carcinoma (LG-
SOC) accounts for approximately 5-10% of serous 
epithelial ovarian cancers with a unique molecu-
lar profile and clinical course (1). It is character-
ized by younger age at presentation, less aggres-
sive biological behavior, lower sensitivity to che-
motherapy, and longer overall survival (OS) 
compared with high-grade serous ovarian carci-
noma (HGSOC) (2). Most LGSOC arise in a slow 
stepwise fashion from a serous cystadenoma or 
adenofibroma, which progresses to the ovary’s se-
rous borderline tumor (SBT). Up to 7% of women 
with SBT develop subsequent carcinoma. Risk fac-
tors for the development of carcinoma include mi-
cropapillary/cribriform subtype, bilateral disease, 
ovarian surface involvement, advanced stage, and 
residual disease after surgery. On histology, LG-
SOC is characterized by small nests, glands, papil-
lae or micropapillae and inverted macropapillae, 
frequently free-floating within unlined clear spac-
es, low-grade cytological atypia (< 3-fold variation 
in nuclear size), and low mitotic activity (3).
Estrogen receptors (ERs) and progesterone 
receptors (PRs) are expressed more frequently in 
LGSOC than in HGSOC (4). LGSOC often harbors 
activating mutations of genes involved in the mi-
togen-activated protein kinase (MAPK) pathway, 
such as KRAS, BRAF, ERBB2, and NRAS. Some-
times it presents driver mutations of PIK3CA, 
FFAR1, USP9X, and EIF1AX linked to the AKT-
mTOR pathway (5). Compared with HGSOC, LG-
SOCs have overexpression of insulin-like growth 
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factor-1 (IGF-1) and a much lower frequency of 
p53 and BReast CAncer (BRCA) gene mutations 
(6,7,8).
TREATMENT OPTIONS FOR LOW-GRADE 
SEROUS OVARIAN CARCINOMA
Surgery
Primary surgery is the cornerstone of the 
treatment of LGSOC (9,10). Patients with disease 
confined to the ovaries should undergo bilateral 
salpingo-oophorectomy, total hysterectomy, and 
comprehensive peritoneal and retroperitoneal 
staging. Fertility-sparing surgery, including uni-
lateral salpingo-oophorectomy, surgical staging, 
and endometrial biopsy, could be taken for young 
women with stage IA-IC1 disease who strongly 
desire to preserve their childbearing potential 
(9,10,11). Patients with advanced disease should 
undergo primary debulking surgery (PDS) to re-
move all macroscopically detectable disease (9,10).
In the GOG 182 trial, comparing carboplatin 
and paclitaxel versus combination with triplet or 
sequential doublet regimens, ancillary analysis as-
sessed survival in 189 patients with FIGO stage 
III-IV LGSOC. The median age was 56.5 years, and 
87.3% had stage III disease. The median follow-up 
time was 47.1 months. The women with no gross 
residual disease after PDS had better progression-
free survival (PFS) (median, 33.2 months) and OS 
(median, 96.9 months) compared with those with 
residual disease 0.1–1.0 cm (14.7 months and 44.5 
months, respectively) and those with residual dis-
ease >1.0 cm (14.1 months and 42.0 months, re-
spectively) (PFS, P < 0.001; OS, P < 0.001). Surgical 
cytoreduction to microscopic residual was associ-
ated with improved PFS and OS in women with 
advanced-stage LGSOC (12). Bogati et al. conduct-
ed a retrospective case series of women affected 
by advanced stage (IIIB or more) LGSOC under-
going surgery in a single Italian oncologic center 
between January 2000 and December 2017. Prima-
ry cytoreductive surgery was performed in 68 of 
72 patients (94%) with FIGO stage IIIB-IV LGSOC 
and achieved no residual disease in 44 patients, 
residual disease <1.0 cm in 49 patients, and resid-
ual disease >1.0 cm in 19 patients. Multivariate 
analysis showed that non-optimal cytoreduction 
was an independent poor prognostic factor for re-
currence risk (HR 2.79; P = 0.021). According to 
multivariate analysis, the absence of significant 
comorbidities (HR 0.56; P = 0.093) and primary in-
stead of interval debulking surgery (IDS) (HR 
2.95; P = 0.027) were independently associated 
with improved overall survival (13).
Secondary cytoreductive surgery (SCS) has a 
role in managing recurrent LGSOC (14,15). A ret-
rospective study of Johns Hopkins Medical Insti-
tutions assessed 26 patients with ovarian micro-
papillary serous carcinoma, of which 21 under-
went SCS and 15 (71%) achieved an optimal 
cytoreduction (residual disease < or = 1.0 cm) (14). 
Bristow et al. showed a single institution retro-
spective trial of patients with recurrent low-grade 
serous carcinoma who underwent SCS between 
1995 and 2012. Forty-one patients met the inclu-
sion criteria. The median time between primary 
tumor debulking and SCRS was 33.2 months. Of 
41 eligible patients who underwent SCS, 32 (78%) 
had the gross residual disease after completing 
secondary surgery. The median PFS for patients 
with no gross residual disease after SCS was 60.3 
months, compared to 10.7 months for patients 
with gross residual disease (P = 0.008). Median OS 
for patients with no gross residual disease was 
93.6 months compared to 45.8 months (P = 0.04). 
These results confirmed a benefit to optimal SCS 
in patients with recurrent low-grade serous carci-
noma (15).
Chemotherapy
LGSOC is indolent neoplasia less responsive 
to chemotherapy both in first-line and in the recur-
rent setting than HGSOC (16,17). A preclinical 
study showed that LGSOC was quite resistant to 
paclitaxel, cisplatin, carboplatin, cyclophospha-
mide, gemcitabine, and less likely to be resistant to 
etoposide, doxorubicin, and topotecan (18). Meta-
analysis of four AGO-OVAR phases III trials, in-
cluding patients with FIGO stage IIIB-IV ovarian 
carcinoma who underwent PDS followed by plati-
num/paclitaxel based regimens, identified 145 pa-
tients with LGSOC, of which 39 had residual dis-
ease > 1.0 cm and were evaluated for response to 
chemotherapy. An objective response was obtained 
in 10 patients (23%), and the response rate was sig-
nificantly lower compared to the 90% response rate 
in 80 women with HGSOC with residual disease > 
1.0 cm (P < 0.001) (16). Gershenson et al. demon-
strated that 62% of women with primary LGSOC 
treated with standard platinum-based chemothera-
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py had persistent disease at the time of second-look 
surgery (19). The response rate to platinum-based 
chemotherapy is significantly lower in women with 
advanced LGSOC than women with HGSOC. Only 
23% of patients with suboptimally debulked dis-
ease responded to adjuvant platinum-based che-
motherapy (17).
Endocrine therapy
Endocrine therapy may provide clinical ben-
efit in women with LGSOC (4,20,21,22,23). Esco-
bar et al. found ER+/PR+ in 21.8%, ER+/PR- in 
17.4%, ER-/PR+ in 13.0%, and ER-/PR- in 47.8% of 
27 LGSOCs and assumed that only the subset of 
tumors with double steroid receptor expression 
could benefit from endocrine treatment (4).
Gershenson et al. analyzed 203 patients with 
FIGO stage II-IV LGSOC after primary cytoreduc-
tive surgery and platinum-based chemotherapy. 
They were randomized in two arms: by endocrine 
therapy in 70 cases and observation in 133 cases. 
Endocrine therapy consisted of letrozole in 38 cas-
es (54.3%), anastrozole in 2 (2.9%), tamoxifen in 20 
(28.6%), leuprolide acetate as single agent or in 
combination in 9 (12.9%), and medroxyprogester-
one acetate in 1 (1.4%) case. Patients who had 
maintenance endocrine therapy had better PFS 
(median, 64.9 versus 26.4 months, P < 0.001) than 
those who had not. Median OS was similar in the 
two groups (115.7 months versus 102.7 months, P = 
0.42) (20). A retrospective study of Johns Hopkins 
School of Medicine, Cleveland Clinic, and Memo-
rial Sloan Kettering Cancer Center assessed 27 pa-
tients with FIGO stage II–IV LGSOC who under-
went either PDS (26 patients) or neoadjuvant car-
boplatin/paclitaxel-based chemotherapy plus IDS 
(1 patient) followed by endocrine therapy, consist-
ing of letrozole (55.5% of cases), anastrozole 
(37.1%) or tamoxifen (7.4%). Six (22.2%) patients 
relapsed after a median time of 21.5 months, 3-year 
PFS was 79.0%, and 3-year OS was 92.6% (21). Wat-
son reported a case report with three years durable 
response to letrozole in a 46-year-old patient with 
rapidly progressive estrogen receptor-positive 
low-grade serous ovarian cancer (22).
A randomized phase III trial compares six 
cycles of carboplatin/paclitaxel chemotherapy fol-
lowed by maintenance letrozole versus letrozole 
monotherapy after PDS in women with stage II-IV 
LGSOC (NRG-GY-019). The findings from this 
study will hopefully provide definitive therapy 
for women with newly diagnosed LGSOC.
The MD Anderson Cancer Center analyzed 
64 patients who received different hormone regi-
mens for recurrent LGSOC. There were six com-
plete responses and two partial responses, for an 
overall response rate of 9.0% in the entire cohort, 
2.7% in platinum-resistant patients, and 13.5% in 
platinum-sensitive patients. The objective re-
sponses were achieved in six of the 33 cases (18.2%) 
treated with letrozole, one of the 21 (4.8%) treated 
with anastrozole, one of the 17 (5.9%) treated with 
tamoxifen, none of the 14 treated with leuprolide 
alone or combined with other agents, and none of 
the four treated with fulvestrant, megestrol ace-
tate or raloxifene. The median to progression was 
7.4 months in the entire cohort, 8.9 months in pa-
tients with ER+/PR+ disease, and 6.2 months in 
those with ER+/PR- disease (23). Anastrozole has 
achieved 3-month clinical benefit (partial response 
+ stable disease) in 23 (63.9%) and a 6-month clini-
cal benefit in 21 (60.8%) of the 36 post-menopausal 
women with ER+ and/or PR+ recurrent/metastatic 
LGSOCs. The median PFS was 11.1 months (24).
Targeted therapy
Based on preclinical research findings, poten-
tial genes or pathways for targeting low-grade se-
rous carcinoma include the angiogenesis path-
way, MAPK pathway, receptor for insulin-like 
grow factor-1 (IGFR-1), and possibly the PI3K/
AKT/mTOR pathway (9,25).
Bevacizumab
For all epithelial ovarian cancers, prospective 
clinical trials have demonstrated improved out-
comes for women treated with bevacizumab in 
the front-line setting, in the platinum-sensitive re-
lapsed setting, and the platinum-resistant relapsed 
setting (26,27,28,29). Although there have not been 
any prospective clinical trials specifically for 
women with low-grade serous carcinoma, a few 
retrospective series have been reported.
Bidus et al. reported three patients with ap-
parent recurrent low-grade serous carcinomas 
treated with bevacizumab. All three patients expe-
rienced a sustained response, two partial respons-
es, and one complete response (30). In 2010, Sch-
meler et al. reported experience in treating 17 
women with recurrent low-grade serous carcino-
ma with bevacizumab. Of 13 patients with mea-
surable disease, five had a partial response, and 
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three had stable disease (31). A retrospective study 
of Memorial Sloan Kettering Cancer Center 
showed that bevacizumab combined with chemo-
therapy offers a treatment strategy for patients 
with low-grade serous ovarian cancer. Of 17 pa-
tients, 15 were evaluable for the primary endpoint 
of the best overall response. Two patients were 
treated with bevacizumab as a single agent, and 
the remainder received bevacizumab in combina-
tion with chemotherapy (paclitaxel, topotecan, cy-
clophosphamide, gemcitabine, or gemcitabine 
and carboplatin). The median duration of bevaci-
zumab administration was 23 weeks. There were 
no complete responses. Partial responses were ob-
served in 6 patients (5 received concurrent pacli-
taxel, and 1 received concurrent gemcitabine). The 
overall response rate was 40%. This study is lim-
ited by small numbers and heterogeneous treat-
ment schedules regarding bevacizumab dosing 
and concomitant therapies. Bevacizumab was ad-
ministered at different doses (15 mg/kg, 10 mg/kg, 
or 7.5 mg/kg). Responses were seen in patients 
treated with each of these doses. No responses 
were seen with bevacizumab as a single agent 
(32). Rose et al. retrospectively analyzed 12 pa-
tients with LGSOC with bevacizumab as a single 
agent (11 patients) or in a combination regimen (1 
patient). Only one patient achieved a partial re-
sponse, but three patients had stable disease after 
progression-free intervals on prior chemotherapy 
of 2.5, 4, and 7 months, respectively. Ten of the 11 
patients were progression-free at six months. The 
median PFS was 48 months. These results showed 
that patients with LGSOC treated primarily with 
bevacizumab as a single agent have a low response 
rate but very long PFS (33).
Another retrospective trial of MD Anderson 
Cancer Center analyzed 45 patients with pretreat-
ed recurrent LGSOC who received bevacizumab 
from 2007 to 2016. Of the 45 patient-regimens, 40 
were evaluable for a response, while five patients 
had no measurable disease. Only three patients 
received bevacizumab as a single agent. The me-
dian number of prior regimens was 4. The average 
duration of bevacizumab treatment was four 
months. Study endpoints included the best re-
sponse, median progression-free survival, median 
overall survival, and toxicity. Complete response 
was seen in 7,5%, partial response in 40% patients 
(16 patients), and 30% of patients (12 patients) had 
stable disease. Disease progression was seen in 
22,5% (9 patients). The median PFS was 10.2 
months. The median OS was 34.6 months. Fifteen 
patients discontinued bevacizumab related to tox-
icity. Bowel perforation and entero-cutaneous fis-
tula occurred in three patients (34).
MEK inhibitors
The high prevalence of MAPK pathway al-
terations in LGSOC has stimulated the evaluation 
of selective MEK inhibitors in patients with this 
malignancy (9,35).
Selumetinib was investigated in a phase II 
trial given (50 mg twice daily orally) to 52 patients 
with recurrent LGSOC. A complete response was 
seen in one patient, and a partial response was 
achieved in seven patients. The objective response 
rate was 15%, and stable disease was observed in 
34 patients. The response to selumetinib was not 
related to RAS/RAF mutational status. The medi-
an time to response was 4.8 months, the median 
duration of response was 10.5 months, and the 
median PFS was 11 months. The most frequent 
adverse events in grade 3 were gastrointestinal 
and dermatologic toxicity (36).
The MILO/ENGOT-ov11, phase III study 
randomized patients with recurrent or persistent 
LGSOC to receive either binimetinib or physi-
cian’s choice chemotherapy (PCC) (liposomal 
doxorubicin, paclitaxel, topotecan), was prema-
turely closed due to futility. Median PFS was 9.1 
months for binimetinib and 10.6 months for PCC 
by blinded independent central review (HR 1.21, 
P=0.807). The ORR by BIRC was 16% for bin-
imetinib and 13% for PCC. In the updated analy-
sis, the ORR by local investigator assessment was 
24% in both groups (37).
Another trial, GOG 0281, was a phase II/III 
trial that investigated trametinib versus PCC (pe-
gylated liposomal doxorubicin or weekly pacli-
taxel, topotecan, letrozole, or tamoxifen) for pa-
tients with recurrent or progressive LGSOC. The 
patient population was pretreated; 48% of patients 
had at least three prior systemic regimens. Con-
troversy to MILO trial, GOG 0281 met its primary 
endpoint, with a median PFS of 13.0 months for 
trametinib and 7.2 months for PCC (HR 0,48, 
P<0,001). The ORR was 26% for trametinib and 
6,2% for PCC, respectively. GOG 0281 was the first 
positive randomized trial with MEK inhibitor in 
women with recurrent LGSOC (38). Fernandez et 
al. compared four different MEK inhibitors (tra-
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metinib, selumetinib, binimetinib, and refame-
tinib) in novel LGSOC patient-derived cell lines 
and found trametinib to have the greatest antipro-
liferative effects. A single dose of trametinib had a 
more significant impact on cellular proliferation 
than 10-fold higher doses of the other drugs (39).
Preclinical and clinical trials have confirmed 
an association between KRAS mutation status and 
response to MEK inhibitors. Although not meet-
ing its primary endpoint, the MILO study demon-
strates that MEK inhibition results in disease con-
trol in a significant number of patients and is a 
strategy that should be seriously considered in 
this difficult-to-treat disease. More importantly, 
there are questions still to be answered regarding 
the extent to which various MAPK mutations con-
fer MEK inhibitor sensitivity (35).
Metformin decreases insulin production, in-
sulin growth factor-1 (IGF-1), and vascular endo-
thelial growth factor, and therefore it exerts anti-
mitotic and anti-angiogenetic effects. In vitro 
studies showed that metformin inhibited all LG-
SOC cell lines. In contrast, trametinib with metfor-
min significantly inhibited the growth of RAS-
mutated LGSOC cell lines but not of cells without 
RAS mutation. Therefore, metformin alone or in 
combination with MEK inhibitors could help 
manage LGSOC (40).
CDK4/6 inhibitors
Endocrine therapy resistance remains a ma-
jor clinical challenge, as patients ultimately suc-
cumb to progressive disease. New therapeutic 
strategies that synergize with endocrine therapies 
are needed to overcome resistance and potentially 
prolong patient survival (41).
Cyclin dependent kinase 4 and 6 inhibitors (ri-
bociclib, palbociclib and abemaciklib) has been ap-
proved by the Food and Drug Administration 
(FDA) and the European Commission as initial en-
docrine-based therapy for postmenopausal women 
with hormone receptor-positive, human epidermal 
growth factor receptor 2 negative advanced breast 
cancer in combination with an aromatase inhibitor 
following a randomized phase III trial (42,43,44).
A phase II study found that ribociclib and le-
trozole combined showed promising activity in 
patients with estrogen receptor-positive ovarian 
cancer and endometrial cancer. The highest bene-
fit was observed in low-grade serous ovarian can-
cers (45). A phase II study is currently assessing 
the combination of letrozole and ribociclib in 
women with recurrent LGSOC. The primary out-
come measure is the response rate. Secondary out-
come measures are clinical benefit rate, toxicity, 
PFS and OS, ER and PR expression, mutation 
analysis of genomic signatures, and Ki-67 expres-
sion. These biological variables will be correlated 
with response and clinical benefit. A pilot phase II 
study of neoadjuvant fulvestrant plus abemaciclib 
every four weeks is ongoing in patients with stage 
III-IV LGSOC. The primary endpoint is the clinical 
benefit rate after four cycles of treatment (9).
CONCLUSION
Low-grade serous carcinoma may occur de 
novo or following a diagnosis of a serous tumor of 
low malignant potential. A young age character-
izes it at diagnosis, relative chemoresistance, and 
prolonged survival compared with HGSOC. Ini-
tial surgical treatment is a primary procedure. 
While platinum/taxane chemotherapy remains 
standard as first-line systemic therapy, there is a 
need for studying new strategies. For recurrent tu-
mors, secondary cytoreduction provides benefit in 
selected patients. Options for systemic therapy 
management include chemotherapy, hormonal 
therapy, or targeted agents. Targeted therapies, 
primarily bevacizumab, MEK inhibitors, and CDK 
inhibitors, alone or in combination with other an-
titumor therapy, are in the focus of several ongo-
ing and future clinical trials. Additional research 
on the genomics of LGSOC, to better define the 
activating gene mutations involved in the carcino-
genesis is strongly warranted to improve this ma-
lignancy prognosis.
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Sažetak
TERAPIJSKI PRISTUP SEROZNOM KARCINOMU JAJNIKA NISKOG GRADUSA
B. Petrić Miše i D. Šundov
Niskogradusni serozni karcinom jajnika (LGSOC) manje je agresivan i ima bolji klinički ishod u usporedbi s visoko-
gradusnim seroznim karcinomom jajnika (HGSOC). Kirurško liječenje s pokušajem maksimalne citoredukcije važno je i 
opravdano zbog relativne kemorezistencije ovog tumora. Stadije bolesti IA-IB trebalo bi klinički pratiti nakon primarne ci-
toredukcije, dok su kliničko praćenje, kemoterapija ili hormonska terapija predložene mogućnosti za stadije bolesti IC-IIA. 
Bolesnice stadija IIB-IV liječe se kemoterapijom sastavljenom od karboplatina i paklitaksela tijekom 6 ciklusa koju slijedi 
hormonska terapija, najčešće inhibitorima aromataze, ili pak samom hormonskom terapijom do progresije bolesti ili nepri-
hvatljive toksičnosti. Kirurško liječenje, kemoterapija i hormonska terapija također se koriste za bolesnice s povratom bole-
sti. U tijeku su klinička istraživanja ciljanom terapijom, posebno s inhibitorima mitogenom-aktiviranih proteinskih kinaza 
(MEK) i inhibitorima kinaza ovisnih o ciklinu (CDK). Dodatna istraživanja genomike LGSOC-a, u cilju boljeg definiranja 
aktivacije genskih mutacija uključenih u karcinogenezu, neophodna su radi poboljšanja prognoze ove zloćudne bolesti.
KLJUČNE RIJEČI: LGSOC, kemoterapija, hormonska terapija, ciljana terapija
